SESSION TITLE: Asthma
SESSION TYPE: Slide Presentations
PRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PM
PURPOSE: Several studies have shown that there is significant clinical improvement, better control of symptoms and reduce of oral corticosteroids and itraconazol, in patients with ABPA treated with omalizumab. The aim of the study was to determine the effect of omalizumab treatment on clinical efficacy in 6 ABPA patients.
METHODS: We followed 6 cases with ABPA treated with omalizumab. Oral and inhaled corticosteroid and itraconazol doses previous and during omalizumab treatment, indication of treatment, spirometric evolution, clinical improvement and side effects, were analyzed.
RESULTS: 6 patients (3 asthma and 3 cystic fibrosis) were recluted. The mean age was 40,67 years. The main purpose of treatment was reducing side effects of maintenance oral corticosteroids therapy in 3 patients, poor clinical control despite optimal treatment in 2 patients and worsening of immunodeficiency due to oral corticosteroids in 1 HIV patient. The mean treatment period was 18 months (±4). The mean prednisone dose was 19 mg daily (±6). Oral corticosteroids were discontinued in 5 patients. Mean BDP equivalent was 1550 µg (±843). 5 patients were treated with itraconazol and it was stopped in all of them. Spirometry was performed in 5 patients: initial mean FEV1% was 58,4 and after 12 months mean FEV1% was 79. ACT values improvement were observed. GETE rating was excellent in 3, good in 2 and moderate in 1 patient. 2 of them developed local erythema.
CONCLUSIONS: In this case series study, all patients had positive clinical response to therapy with omalizumab, showing a good safety profile. Oral corticosteroids and itraconazol were discontinued in the majority of them.
CLINICAL IMPLICATIONS: Although Omalizumab treatment is not already indicated, there are some reports about successful response to Omalizumab in cystic fibrosis or asthma complicated with ABPA. According to this case series study, as well as in previous reports, the use of Omalizumab to control ABPA in steroid dependent patients is recommended. Further studies are needed to define its therapeutical role.
DISCLOSURE: The following authors have nothing to disclose: María del Valle Somiedo Gutiérrez, Carolina Cisneros, Rosa Girón Moreno, Gilda Fernandes Vasconcelos, Gonzalo Segrelles, Silvia Sanchez
Omalizumab treatment is not already indicated but there are some reports about successful response to Omalizumab in cystic fibrosis or asthma complicated with ABPA.